Orchid Pharma soars on getting EIR report from USFDA for Chennai facility

09 Jan 2018 Evaluate

Orchid Pharma is currently trading at Rs. 24.55, up by 1.15 points or 4.91% from its previous closing of Rs. 23.40 on the BSE.

The scrip opened at Rs. 24.55 and has touched a high and low of Rs. 24.55 and Rs. 24.55 respectively. So far 258920 shares were traded on the counter.

The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 39.70 on 18-Apr-2017 and a 52 week low of Rs. 16.70 on 16-Sep-2017.

Last one week high and low of the scrip stood at Rs. 24.55 and Rs. 19.25 respectively. The current market cap of the company is Rs. 218.41 crore.

The promoters holding in the company stood at 26.68%, while Institutions and Non-Institutions held 4.78% and 68.54% respectively.

Orchid Pharma has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) based on the successful inspection closure for the Post-marketing Adverse Drug Experience reporting inspection (PADE) conducted at Orchid Towers 313, Valluvar Kottam High Road, Nungambakkam, Chennai, Tamil Nadu, India. The facility was inspected by USFDA in the month of June 2017.

Orchid Pharma is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients and finished dosage forms. It is also engaged in research of new drugs.

Orchid Pharma Share Price

689.80 -16.95 (-2.40%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×